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Summary
Urokinase plasminogen activator receptor (uPAR) activates 51 integrin and ERK signaling, inducing in vivo proliferation
of HEp3 human carcinoma. Here we demonstrate that EGFR mediates the uPAR/integrin/fibronectin (FN) induced growth
pathway. Its activation is ligand-independent and does not require high EGFR, but does require high uPAR expression.
Only when uPAR level is constitutively elevated does EGFR become 51-associated and activated. Domain 1 of uPAR is
crucial for EGFR activation, and FAK links integrin and EGFR signaling. Inhibition of EGFR kinase blocks uPAR induced
signal to ERK, implicating EGFR as an important effector of the pathway. Disruption of uPAR or EGFR signaling reduces
HEp3 proliferation in vivo. These findings unveil a mechanism whereby uPAR subverts ligand-regulated EGFR signaling,
providing cancer cells with proliferative advantage.
Introduction their heterogeneity, there is less understanding of the role of
integrin and EGFR signaling in proliferation of tumor cells in
culture, and the impetus for their in vivo proliferation is evenMechanisms responsible for elaboration of growth-stimulating
signals and molecular events responsible for their sensing are less well understood. It is thought that tumor cells in culture
elaborate their own growth factors, including EGFR ligandsderegulated in cancer cells. In normal cells, activation of MAPK-
ERK and growth stimulation require a functional collaboration (Schlessinger, 2000), and use them in an autocrine fashion, but
that their dependence for growth on integrin-mediated adhesionbetween secreted growth factor(s) and adhesion-dependent
signaling events (Giancotti and Ruoslahti, 1999). Integrins can and signaling is either unnecessary or dispensable (Ruoslahti,
1999). However, these conclusions were mainly derived fromactivate ERK through their  subunit using caveolin and Shc
(Wary et al., 1998), and/or through the  subunit and focal the study of cells grown in agar or as monolayers, i.e., under
conditions that do not mimic those existing in vivo, where cellsadhesion kinase (FAK) (Keely et al., 1998; Cary and Guan, 1999;
Giancotti and Ruoslahti, 1999). Potentiation by integrins of are organized in three-dimensional structures which receive,
and must interpret and integrate, multiple signals (Bissell et al.,growth factor-induced ERK activation is most evident when the
integrins are aggregated and bound by ligand (Miyamoto et al., 1999).
We previously showed that highly malignant human carci-1996). There is evidence to suggest that clustering of integrins
leads to clustering of EGFR and its crossphosphorylation (Miya- noma T-HEp3 cells grow rapidly in vivo, and have a very high
level of active ERK (Aguirre Ghiso et al., 1999). This activity wasmoto et al., 1996), and that the process involves FAK-dependent
signaling (Sieg et al., 2000). Cooperation between integrins and dependent on high expression of urokinase receptor (uPAR).
The fact that there is substantial published evidence to docu-EGFR in normal cell signaling is further supported by evidence
that, even in absence of EGF, EGFR can become activated, ment overexpression of uPAR in most malignant cancers and
to show that its expression is a predictor of poor prognosis inleading to activation of ERK, increased cell survival, and partial
(G1/S) traversal of the cell cycle (Moro et al., 1998). This is cancer (for review see Andreasen et al., 1997; Schmitt et al.,
2000) underscores the relevance of our finding. We found thataccomplished through a physical interaction between 51 in-
tegrins and EGFR, and it occurs in cells with relatively high the overexpressed uPAR interacted with and activated 51-
integrin. This activation was maximal when uPAR was boundEGFR expression (Moro et al., 1998). However, even under these
conditions, exogenous growth factors are necessary to cause to uPA and 51 to FN. In HEp3 cells in which the level of uPAR
was diminished by prolonged culture (D-HEp3), or by stablecell progression through G2/M (Moro et al., 1998). Because of
S I G N I F I C A N C E
Cancer cells notoriously evade host-imposed growth inhibition, often by constitutively activating autocrine growth pathways or
overexpressing surface receptors. We identified a mitogenic pathway whereby a squamous carcinoma with overexpressed urokinase
receptor (uPAR) and a normal level of EGFR utilizes uPAR to activate a ligand-independent EGFR signal in vivo. This is important in
view of current clinical trials utilizing antibody blockade of ligand binding to EGFR. Since many malignant tumors overexpress uPAR,
they may stimulate EGFR signaling in spite of normal EGFR levels and absent ligand-producing capacity. Patients with such tumors
may fail on anti-EGFR antibody therapy, requiring interventions that consider the role of uPAR in promoting tumor growth. Our
characterization of uPAR-dependent steps that culminate in tumor growth may provide opportunities for therapeutic interventions.
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transfection with a plasmid expressing uPAR-antisense (AS24), unstimulated (adherent to PLL) T-HEp3. More importantly, a
strong stimulation was observed only in these cells, after adhe-fewer uPAR/51 complexes were formed and the signal to
ERK was reduced to the level that allowed their in vivo survival sion to FN (Figure 1E). Similar results were obtained when LK25
and AS24 cells were compared (Figure 1F). Thus, it appearsbut precluded growth, forcing them into a state of dormancy
(Yu et al., 1997; Aguirre Ghiso et al., 1999). Because integrin- that it is the uPAR, and not the 51 integrin presence or EGFR
level, that determine its activation. Since each of the cell typesinduced activation of EGFR has been linked in some cells to
EGFR overexpression (Moro et al., 1998), and since HEp3 cells examined expresses similar levels of 51-integrin (Aguirre
Ghiso et al., 1999, 2001), and since EGFR becomes tyrosine-are derived from a head and neck tumor known to overexpress
this growth factor receptor (Nicholson et al., 2001), we wondered phosphorylated upon cell adhesion to FN only in T-HEp3 and
LK25 cells, which have low EGFR levels, we had to assume thatwhat role, if any, EGFR played in ERK activation and growth
of these cells. Preliminary data showed that, contrary to the mechanisms other than EGFR overexpression, possibly involving
an autocrine loop, must be responsible for its activation.expected, D-HEp3 cells expressed much higher EGFR levels
than T-HEp3 cells, but the receptor was not phosphorylated. We compared the expression of known EGFR-ligands EGF,
TGF, -cellulin, HB-EGF, and amphiregulin in T- and D-HEp3This suggested that the mere presence of 51 integrin and
high levels of EGFR, thought to be sufficient for EGFR activation cells. We found that the expression of EGF, -cellulin, and am-
phiregulin was undetectable even by RT-PCR, and TGF wasupon adhesion to FN (Moro et al., 1998), may not be adequate
to induce receptor activation and proliferation in all cell types. detectable only by PCR and only in D-HEp3 cells, while HB-
EGF, detectable by both RT-PCR (results not shown) and North-Our previous work indicated that T-HEp3 cells are highly depen-
dent on FN-generated, uPAR/integrin-transduced signals for ern blot, was similarly expressed in D- and T-HEp3 cells (Figure
2B). To rule out the possibility that it was not the overall leveltheir in vivo growth (Aguirre Ghiso et al., 1999, 2001). Here
we provide novel information that strongly implicates uPAR in of HB-EGF but the ability of T-HEp3 cells to process it to a
mature form (Goishi et al., 1995) that was responsible for EGFRregulation of EGFR activity in culture and, most importantly, in
vivo. Our data identify EGFR as the mediator of signals initiated activation, we tested the effect of medium conditioned by
T-HEp3 cells on the EGFR and ERK activation in D-HEp3 cells.by the uPA/uPAR/FN/51 complex that result in the very high
and persistent level of ERK activity necessary for the in vivo While treatment of D-HEp3 cells with 20 ng/ml EGF induced
both EGFR and ERK phosphorylation, indicating that the recep-growth of HEp3 cancer cells.
tor and the signaling pathway were intact, T-HEp3 conditioned
medium was ineffective (Figure 2C). In addition, exogenous HB-Results
EGF stimulated EGFR phosphorylation in T-HEp3, and this stim-
ulation was sensitive to inhibition by CRM197 (a mutant diphthe-We previously linked high uPAR expression to its frequent inter-
actions with 51-integrin, high ERK activity, and in vivo growth ria toxin that blocks mitogenic activity of HB-EGF) (Mitamura
et al., 1995) (Figure 2D). In contrast, neither the basal EGFRof T-HEp3 cells (Aguirre Ghiso et al., 1999). Because ERK is
also a downstream effector of both integrins and EGFR, we phosphorylation nor the phosphorylation induced by adhesion
to FN was affected by CRM197 (Figures 2D and 2E).have now investigated the potential role of this growth factor
receptor in the chain of events leading from high uPAR expres- Overall, these results show that in HEp3 cells, EGFR activa-
tion is independent of an autocrine loop, and that 51-integrinsion to T-HEp3 tumorigenicity.
and high EGFR expression is not sufficient for FN-induced EGFR
activation. The results also show a correlation between EGFR-Level of EGFR expression and its state of activation
We assayed EGFR in lysates of uPAR-rich tumorigenic HEp3 activation and uPAR expression.
(T-HEp3 and LK25) cells and uPAR-poor, dormant HEp3
(D-HEp3 and AS24) cells by Western blotting. We found a 5-fold Effect of uPAR on 51-EGFR interaction
and EGFR signalinggreater EGFR-protein content in D-HEp3 and AS24 cells (Fig-
ures 1A and 1F), and this result was corroborated by FACS To consider the role of uPAR in the regulation of EGFR activation
and the involvement of integrins in this process, we first exploredanalysis of surface expression of EGFR (Figure 1B). This finding
was surprising, because EGFR overexpression is known to re- whether there was a physical interaction between 51 and
EGFR and whether this interaction was uPAR-dependent. T-sult in its autophosphorylation and signaling (Schlessinger,
2000), and our previous results showed that ERK activity was and D-HEp3 cell lysates were immunoprecipitated either with
anti-1 (Figure 3A) or anti-EGFR (Figure 3B) antibodies andvery low in D-HEp3 cells (Aguirre Ghiso et al., 1999). We then
monitored EGFR autophosphorylation in serum-starved T-HEp3 blotted with anti-1 and anti-EGFR antibodies, respectively.
Although T-HEp3 and D-HEp3 cells contain a similar amountand D-HEp3 cells using direct Western blotting with antiactive
EGFR antibodies (Figure 1C) or EGFR immunoprecipitation fol- of 1 integrin, EGFR was associated with 1 only in uPAR-rich
T-HEp3 cells. In a parallel experiment, anti-EGFR antibodieslowed by Western blotting with antiphosphotyrosine antibodies
(Figure 1D). In spite of their low EGFR content but in agreement pulled down much more EGFR from the D-HEp3 cells, but the
relative amount of coimmunoprecipitated 1 integrin was muchwith their high ERK activity, we found a 7- to 10-fold greater
level of phospho-EGFR in T-HEp3 cells. Published data indicate smaller than in T-HEp3 cells (Figure 3B). Similar results were
obtained when LK25 and AS24 cells, plated on FN and thenthat EGFR becomes tyrosine-phosphorylated when cells ex-
pressing 51 integrin and abundant EGFR are allowed to ad- lysed, were immunoprecipitated with anti-51 antibody. Thus,
more EGFR was associated with 51 integrin in uPAR-richhere to FN (Moro et al., 1998). Therefore, we tested the effect
this treatment had on EGFR activation in T-HEp3 and D-HEp3 LK25 cells. More importantly, in LK25 cells, EGFR present in
the complex with integrin was phosphorylated (Figure 3C),cells; adhesion to poly-L-lysine (PLL) served as a negative con-
trol. We found that the level of phospho-EGFR was higher in whereas no phosphorylated population was detectable in AS24
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Figure 1. EGFR content, state of activation, and
effect of cell binding to FN in uPAR-rich and
uPAR-deficient HEp3 cells
A: Cell lysates from serum-starved T-HEp3 (T) and
D-HEp3 (D) cells, immunoblotted with polyclonal
EGFR antibody (top) for total EGFR content and
anti-ERK (MK12) antibody for loading control
(bottom). The graph shows EGFR/ERK ratio ob-
tained by densitometric scanning (see Experi-
mental Procedures).
B: Surface expression of EGFR was measured us-
ing FACS analysis as described in Experimental
Procedures.
C: Cell lysates from serum-starved T-HEp3 (T) and
D-HEp3 (D) cells were immunoblotted for active-
EGFR (mAb 74, top) and total EGFR (polyclonal
anti-EGFR, bottom). Active-EGFR/EGFR ratio was
determined as in A (graph).
D: EGFR was immunoprecipitated from 800 g of
T-HEp3(T) and D-HEp3(D) NP-40 buffer cell lysate
protein (see Experimental Procedures) using
mouse anti-EGFR antibody (mAb 225, 3 g), and
the resulting immunoprecipitates (IP) were ana-
lyzed by IB for phosphotyrosine (PY-20, top) or
total EGFR (polyclonal anti-EGFR, bottom). The
phospho-EGFR (P-EGFR)/total EGFR ratio was ob-
tained as in A (graph).
E: T-HEp3 (T) and D-HEp3 (D) were plated on FN
(or PLL as negative control) for 20 min. EGFR was
immunoprecipitated from 1 mg of cell lysate pro-
tein as in D, split equally into two aliquots and
immunoblotted for phosphotyrosine (RC-20, top)
and total EGFR (bottom).
F: As in E except comparing LK25 (uPAR-rich) and
AS24 (uPAR-deficient) cells.
cells. Additional support for uPAR regulation of EGFR associa- neously distributed in the plasma membrane, in the T-HEp3
cells, the staining of active EGFR was much more intense andtion with 51 integrins was obtained from a fibrosarcoma cell
line, HT1080, transfected with uPAR-antisense under an induc- was concentrated in focal areas and in cell-cell junctions (Figure
3D, center column). An overlay of the 1 and the active EGFRible promoter. While EGFR was found to be integrin-associated
in HT1080 cells expressing uPAR (in presence of tetracycline), images showed a high degree of colocalization, suggesting mo-
lecular proximity between the integrin and active EGFR (Figureupregulation of the antisense by removal of the antibiotic from
the incubation medium reduced uPAR level by 90% and re- 3D, right column) and supporting the coimmunoprecipitation
data (Figures 3A–3C).duced 51 integrin-associated EGFR protein to barely detect-
able levels (results not shown). Taken together, these findings Activation of ERK is an important downstream target of
active EGFR. To test whether EGFR activated by uPAR signaledshow that it is not the levels of EGFR or the 51 integrin, which
do not change upon uPAR-antisense induction in HT1080 cells, to ERK, serum-starved T-HEp3 cells plated on FN, or on PLL
as negative control, were examined for phospho-EGFR andbut the abundance of uPAR that determines EGFR-integrin inter-
action and EGFR phosphorylation following adhesion to FN. phospho-ERK content. As shown in Figure 4A, the increase in
phospho-EGFR correlated with increased ERK activity.To confirm this conclusion in intact cells, we used fluores-
cence confocal microscopy. We have previously shown using Because we had shown earlier that uPAR interaction with
51 integrin resulted in a potent ERK activation in T-HEp3this method that most of the surface expressed uPAR coloca-
lized with 1 integrin in T-HEp3 cells (Aguirre Ghiso et al., 2001). cells (Aguirre Ghiso et al., 1999), we wondered whether ERK
activation induced by EGFR and by the uPAR-activated integrinsWe now tested the surface localization of EGFR and 1 integrin
in uPAR-rich and uPAR-poor cells using antibodies to 1 and was a result of converging or separate pathways. To test this,
we examined the effect of inhibition of EGFR kinase activity onthe phosphorylated (active) form of EGFR. The levels and distri-
bution of 1 integrin were similar in T and D-HEp3 cells (Figure ERK activation by two independent approaches. First, T-HEp3
cells were preincubated for 15 min with or without a pharmaco-3D, left column). However, while in the D-HEp3 cells the staining
of active EGFR was of a very low intensity and was homoge- logical inhibitor of EGFR-kinase, AG1478, before plating on FN
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Figure 2. Analysis of expression of EGFR ligands
in T and D HEp3 cells
A: RT-PCR analysis for expression EGF, amphire-
gulin, -cellulin, and TGF- (top panels) was per-
formed on total RNA preparations from serum-
starved T-HEp3 (T) and D-HEp3 (D) cells. RT-PCR
of GAPDH served as loading control (bottom
panels). Shown, ethidium bromide stained bands
in 1% agarose gel. Positive controls (): RNA from
LnCAP cells for EGF; from MDA231 cells for TGF-
and -cellulin; 300 bp PCR fragment for amphire-
gulin. Negative control (): no RNA template.
B: Northern blot analysis for TGF- (with positive
control RNA from MDA231 cells) and HB-EGF (in
duplicate) mRNA. GAPDH used as loading con-
trol (top and bottom).
C: D-HEp3 cells, serum-starved for 24 hr, were
treated for 20 min with EGF (20 ng/ml), condi-
tioned medium (48 hr in serum-free medium) of
D-HEp3 (Dcond m) or T-HEp3 (T cond m) cells, or fresh
medium. Cell lysates (50g protein) were blotted
for phosphorylated ERK (P-ERK, mAb E-4) and to-
tal ERK (top panels). EGFR immunoprecipitated
from the same cell lysates (500 g protein with
5 g mouse Ab5) was blotted for phospho-EGFR
and total EGFR (bottom panels).
D: T-HEp3 cells, serum-starved for 24 hr were
treated for 20 min with CRM197 (10 g/ml) or
kept untreated. To ensure specificity, cells were
then treated with HB-EGF (20 ng/ml) or medium
alone in the presence or absence of CRM197
(10 g/ml) for 5 min. Immunoprecipitated EGFR
was blotted for phosphotyrosine (RC-20, top)
and total EGFR (bottom).
E: T-HEp3 cells, serum-starved and treated
with CRM197 as in D, were plated on FN (or PLL as negative control) for 20 min. EGFR was immunoprecipitated from 1 mg of cell lysate protein as in Figure
1D and analyzed for phosphotyrosine (top) and total EGFR (bottom).
or PLL (Figure 4A) and collecting the cells 20 min later for analy- cells formed small tumors in which the cell number was reduced
by60% on day 5. In a parallel experiment, treatment of T-HEp3sis. As shown in Figure 4A, this inhibitor blocked both the basal
and the FN-stimulated EGFR phosphorylation, but only the cells with AG1478 (0, 0.5, 1, and 5 M) for 3 days in culture
produced no inhibition of cell growth (results not shown). TheFN-stimulated ERK phosphorylation was blocked (Figure 4A).
This suggests that EGFR kinase activity is required for the propa- result of the in vivo experiment demonstrates that EGFR signal-
ing is required for the full proliferative potential of uPAR-richgation of the FN-dependent signal to ERK, and that there is an
additional ERK-activating “constitutive” FN-independent path- T-HEp3.
way of low efficiency that appears to be EGFR independent.
We also used genetic approach whereby T-HEp3 cells were The mechanism of EGFR activation by uPAR
transiently transfected with a C-terminal truncated form of To test the role of uPAR in EGFR activation directly, uPAR
EGFR, CD533 (Spivak-Kroizman et al., 1992; Redemann et al., expression was restored in D-HEp3 cells (Figure 5A, insert) to
the level found in T-HEp3 cells (Aguirre Ghiso et al., 2001). We1992), which functions as a dominant negative EGFR, presum-
ably by forming heterodimers with the wild-type receptor. The previously showed that reexpression of uPAR interrupted the
in vivo dormancy of D-HEp3 cells, yielding cells capable of indominant negative mutant was expressed in excess of the na-
tive, wild-type EGFR, and it strongly reduced the FN-induced vivo growth (Aguirre Ghiso et al., 2001). We now tested whether,
similar to the parental T-HEp3 cells, these cells utilized uPAR-tyrosine phosphorylation of EGFR, suggesting that homodimer-
ization of wt EGFR is required (Figure 4B). This reduction was induced and ligand-independent EGFR activation to generate
their mitogenic signals. The results in Figure 5A confirmed thatlinked to a similar reduction in phospho-ERK (Figure 4B, lower
panel). Together, these results directly implicate EGFR as a uPAR reexpression restores the in vivo proliferation of these
cells. Moreover, while pretreatment with AG1478 reduced theirdownstream effector of uPAR and 51 signal transduction that
leads to ERK activation in an uPAR-rich environment. growth in vivo, pretreatment with an EGFR-blocking antibody
did not (Figure 5A, top and bottom panels). Thus, it appearsTo test the contribution of this pathway to growth in vivo,
T-HEp3 cells (5  105 ), pretreated with 1 M AG1478 for 24 hr that the tumorigenic phenotype restored by uPAR reexpression
possesses the hallmarks of the parental T-HEp3 cells. In orderunder serum-free conditions, or kept in medium alone, were
inoculated on to the CAMs of chick embryos. Untreated T-HEp3 to strengthen this conclusion, we tested whether uPAR reex-
pression induced integrin/EGFR association characteristic ofcells grew rapidly on the CAM, forming large tumors containing
107 cells by day 5 (Figure 4C), while the AG1478 pretreated the uPAR-rich T-HEp3 cells (Figure 3). Pools of vector and uPAR
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Figure 3. EGFR/51 integrin association and
EGFR activation correlates with uPAR expression
A: Cell lysates from serum-starved T-HEp3 (T) and
D-HEp3 (D) cells were incubated with anti-1 an-
tibody (mAb TS2/16, 5 g) (IP 1) or isotype
matched IgG (IP IgG). The immunoprecipitates
were blotted for 1 (4B7R, top) and total EGFR
(bottom). EGFR/1 ratio obtained as in Figure 1A
(graph). D-HEp3 total protein lysate was blotted
as positive control.
B: Same as in A except immunoprecipitated with
anti-EGFR (mouse Ab5, 5 g). 1/EGFR ratio ob-
tained as in Figure 1A (graph).
C: LK25 (uPAR-rich) and AS24 (uPAR-deficient)
cells were plated on FN or on PLL as negative
control for 20 min. 51-integrin was immunopre-
cipitated from 800 g of cells protein with 5 g of
VLA5 antibody and blotted for phosphotyrosine
(RC-20, top) and 5 (polyclonal anti-5; bottom).
Phosphotyrosine blot was stripped and reblotted
for total EGFR (middle panel).
D: Colocalization of active EGFR and1 integrins.
T-HEp3 and D-HEp3 were plated on glass cov-
erslips and immunostained for 1 (in green) and
activated EGFR (in red; act-EGFR). Overlay is
shown in yellow. DAPI stained nuclei are in blue.
Active EGFR colocalizes with 1-integrin only in
uPAR-rich, T-HEp3 cells.
transfected cells were lysed and immunoprecipitated using anti- or antibody treatment, and that reexpression of uPAR produces
a similar effect.1 antibody and blotted with anti-EGFR and anti-5 antibodies.
To gain further insight into the structure/function relation ofThe results in Figure 5B (bottom) show that a similar level of
uPAR as an inducer of EGFR activation, we prepared a truncatedthe 5 integrin subunit was pulled down with the anti-51
uPAR lacking domain 1 (D1) (referred to as D2D3), and a mutantantibody, indicating that there was no major change in the 51
in which the protease sensitive sites in the linker peptide be-integrin level upon uPAR reexpression. However, EGFR was
tween D1 and D2 were mutated (referred to as noncleavable,found to be associated with the integrin only in cells that reex-
nc), making it resistant to protease cleavage (Hoyer-Hansen
pressed uPAR (Figure 5B, top). This result implicated uPAR in et al., 1992). D-HEp3 cells were transfected, and hygromycin-
regulation of integrin/EGFR interaction. We previously showed resistant pools of cells were obtained that expressed the mutant
that lateral interaction of uPAR with 51 leads to integrin acti- uPAR at levels similar to that obtained for full-length uPAR
vation and function as measured by the ability to assemble FN (Figure 5E). The effect of modification of uPAR structure on the
fibrils (Aguirre Ghiso et al., 2001), phosphorylation of FAK and FN-induced EGFR activation was tested. As shown in Figure
activation of ras (Aguirre Ghiso, 2002), initiation of an intracellu- 5F, left panel, the FN-induced EGFR activation was marked in
cells transfected with the wild-type uPAR, and even strongerlar signal (Aguirre Ghiso et al., 2001), presumably through an
in cells transfected with the noncleavable uPARnc mutant.“outside-in” mechanism, and, as shown here, activation of
Quantitative analysis of 3 experiments (Figure 5F, right panel)EGFR. To further explore the nature of 51-integrin activation
confirmed these results and also showed that cell transfectedby uPAR and its effect on EGFR phosphorylation, we compared
with the mutant missing domain 1 (D2D3) were unable to activateits effect to the effect of known “outside-in” 51-integrin acti-
EGFR when plated on FN. This suggests that optimal uPAR-vators, Mn2 and a 1-activating antibody, TS2/16, which in-
integrin interaction depends on the D1 domain and that un-
creased the binding of 125I-labeled FN to D-HEp3 cells and adhe- cleaved uPAR is most effective in EGFR activation.
sion of these cells to FN (results not shown and Aguirre Ghiso
et al., 1999). As shown in Figures 5C and 5D, both treatments FAK links intracellular signaling of uPAR/integrin
strongly increased FN-induced EGFR-phosphorylation. These and EGFR
results show that, although, under basal conditions, the 51- The experiments illustrated in Figures 4A and 4B show that
pharmacologic and genetic inhibitors of EGFR kinase blockintegrin in D-HEp3 cells is inactive, it can be activated by Mn2
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Figure 4. Functional EGFR kinase is required for
integrin-mediated EGFR activation and in vivo
growth of uPAR-rich HEp3 cells
A: T-HEp3 pretreated with () AG1478 (AG) or
untreated () were plated on FN, or on PLL as
negative control, for 20 min. Immunoprecipi-
tated EGFR was blotted for phosphotyrosine (RC-
20, top panel) and total EGFR (top panel, bot-
tom). Cell lysate protein was analyzed for P-ERK
(third panel) and ERK (bottom panel) by direct
IB.
B: T-HEp3 cells transfected with vector (Tvec) or
with CD533-EGFR (T533) were plated on FN or PLL.
Efficiency of transfection of T-HEp3 using a plas-
mid coding for GFP under the same promoter as
the CD533 was determined to be greater than
40%. Immunoprecipitated EGFR was analyzed
for P-EGFR (top panel), EGFR (mAb 14; second
panel), P-ERK (third panel), and ERK (bottom
panel) as in A.
C: Growth of T-HEp3 cells pretreated with
AG1478, or untreated, on the CAM (see Experi-
mental Procedures). Each point represents the
mean  SE of five samples. *P  0.0001 T-HEp3
control versus T-HEp3  AG1478 as determined
by ANOVA test.
almost entirely the uPAR and FN-induced ERK activation, sug- with the EGFR pulled down from the uPAR-rich T-HEp3 tumors.
Using specific antibodies, we identified the125 kDa phospho-gesting that the pathways from integrin and from EGFR to ERK
are functionally linked. We previously found that FAK associates protein as FAK (Figure 6A, middle panel). We also found that
Ras, previously shown to be more active in T-HEp3 cells (Aguirrewith 1-integrin in HEp3 cells (Aguirre Ghiso, 2002). In an at-
tempt to identify the site of crossover between the 51-integrin Ghiso, 2002), was preferentially associated with the EGFR com-
plex in vivo in T-HEp3 cells, suggesting that the Ras-ERK activa-and EGFR pathways, we considered the recently published evi-
dence suggesting that FAK may act as a receptor-proximal tion signal is initiated by EGFR (results not shown). Although the
additional EGFR-associated phosphoproteins are still awaitingbridging protein between growth factor receptors and integrin
signaling (Sieg et al., 2000). Specifically, we examined whether identification, it appears that EGFR is part of a large in vivo
complex of potential signaling proteins, which is absent fromthe presence of EGFR-FAK association exists in vivo and in
culture. T-HEp3 cells (2 105 ) and D-HEp3 cells (1.2 106 ) were uPAR deficient D-HEp3 cells.
To test the role of FAK in uPAR-mediated EGFR activation,inoculated on the chorioallantoic membrane (CAM) of chick
embryos and incubated for 7 days. T-HEp3 cells grew into large we immunoprecipitated EGFR from T-HEp3 cells, blotted the
proteins with anti-phosphotyrosine antibody, and then strippedtumors, while the D-HEp3 cells formed small nodules with little
or no increase in cell number, confirming their in vivo dormancy and blotted for EGFR or FAK. The results show that in uPAR-
rich cells, FAK can be coimmunoprecipitated with EGFR, and(Ossowski and Reich, 1980; Aguirre Ghiso et al., 1999). One
T-HEp3 tumor and ten D-HEp3 nodules were collected in lysis that the EGFR-associated FAK is phosphorylated, suggesting
the requirement for functional FAK (Figure 6B). To determinebuffer, immunoprecipitated with anti-EGFR antibodies, and
blotted for phospho-tyrosine. Unlike in the D-HEp3 cell culture, whether active FAK was required for integrin/EGFR complex
assembly or for downstream signaling, T-HEp3 cells were trans-the total level of EGFR was somewhat lower in the D-HEp3
nodules, most likely due to dilution of the sample with host cell fected with FRNK, a natural splice variant of FAK that has been
shown to displace FAK from integrin association and to blockproteins. Nevertheless, it can be seen that the ratio of phospho-
EGFR to EGFR was much lower in D-HEp3 nodules than in FAK activity in several cell lines (Cary and Guan, 1999; Sieg et
al., 2000), including the T-HEp3 cells (Aguirre Ghiso, 2002). TheT-HEp3 CAM tumors (Figure 6A). More importantly, a large num-
ber of phosphoproteins were found to coimmunoprecipitate EGFR/integrin association was probed in vector and FRNK-
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Figure 5. Mechanism of integrin-activation-dependent EGFR stimulation by uPAR
A: D-HEp3 cells transfected with vector (Dvec) or wild-type uPAR (DuPAR) pretreated with 1 M AG1478, or untreated (top graph), or with mAb 225 (IgG as
control) (bottom graph) were analyzed for growth after 96 hr on the CAM (see Experimental Procedures). Each bar represents the mean  SD of five
samples. *P  0.001 DuPAR versus DuPAR with AG1478 and **P  0.05 Dvec versus DuPAR with IgG as determined by Student’s t test. There was no significant
difference in DuPAR growth between IgG and mAb 225 treated cells. Expression of the transgene was tested by IB with anti-uPAR antibody (R2) and ERK as
loading control (insert).
B: 51-integrin was immunoprecipitated from 800 g of Dvec and DuPAR lysate protein with 5 g of VLA5 antibody and blotted for EGFR (top) and 5
(polyclonal anti-5; bottom). Isotype-matched IgG was used as control.
C: D-HEp3 cells without or with 1.5 mM MnCl2 were plated on FN (see Experimental Procedures). EGFR was immunoprecipitated from 1 mg of total cell
lysate protein as in Figure 1D, split equally into two aliquots, and blotted for phosphotyrosine (RC-20, top) and total EGFR (bottom).
D: D-HEp3 cells treated with anti-1 activating antibody, TS2/16, or isotype-matched IgG were plated on FN or PLL and processed as in C for phosphotyrosine
(top) and total EGFR (bottom).
E: D-HEp3 cells transfected with vector (Dvec) or vector expressing wild-type uPAR (DuPAR), mutant-D2D3, and noncleavable uPAR (Dnc) expressed similar level
of the protein, as determined by IB.
F: Transfected cells (see E) were plated on FN or PLL and processed as in C for phosphotyrosine (top) and total EGFR (bottom). Columns in graph represent
mean EGFR activation on FN (minus PLL background) as determined by densitometry of bands from three independent experiments. Error bars represent
SEM.
transfected cells by immunoprecipitation of cell lysates with to activate EGFR when plated on fibronectin (Figure 6D). This
result suggests that functional FAK is required for uPAR-medi-anti-EGFR antibody followed by blotting with anti 5 antibody.
ated activation of EGFR in HEp3 tumor cells and that it mayThe results (Figure 6C) show that expression of FRNK reduced
serve to integrate integrin and EGFR signaling even in absencethe integrin/EGFR association, suggesting that FAK may be
of EGFR ligand.important in complex assembly. The requirement for functional
FAK in FN-induced EGFR activation was further examined in
vector and FRNK-expressing cell by plating the cells on PLL or Dependence of EGFR activation on an intact uPA/
uPAR-FN/integrin complex in culture and in vivoFN and blotting for phospho-EGFR in immunoprecipitates of
EGFR. While adhesion to FN induced EGFR phosphorylation in We have previously shown that binding of uPA to uPAR leads
to a robust ERK activation (Aguirre Ghiso et al., 1999). To testvector transfected cells, T-HEp3 cells expressing FRNK failed
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Figure 7. EGFR kinase as a mediator of uPA/uPAR/integrin-induced EGFR
signaling to ERK
A: T-HEp3 cells were stripped of endogenous uPA and treated with or without
single chain uPA (10 nM) for 10 min (see Experimental Procedures). Cell
lysate was incubated with anti-EGFR (mAb 225) or control IgG antibodies,
and the immunoprecipitates were blotted for 5 (top) and total EGFR
(bottom).
B: T-HEp3 cells were stripped as in A and incubated with or without single
chain uPA and with or without 1 M AG1478 for 10 min. EGFR was immuno-
precipitated as in Figure 1D, and blotted for phosphotyrosine (RC-20, top
panel) and total EGFR (second panel). Cell lysate protein was analyzed for
P-ERK (third panel) and ERK (bottom panel) by direct IB.Figure 6. The role of FAK in uPAR-dependent EGFR activation in culture and
C: T-HEp3 cells treated with anti-uPAR antibody (R2), isotype matched IgGin vivo
(IgG), or medium alone (DB) were plated on FN or PLL. EGFR and P-EGFR
A: T-HEp3 (T) and D-HEp3 (D) cells were inoculated and grown on the CAM
were determined as in B.
for seven days and processed as described in Experimental Procedures.
1.5 mg of protein from whole tumor lysates was immunoprecipitated with
anti-EGFR antibody (mAb 225, 3 g) and blotted for phosphotyrosine (RC-
20, top). The membrane was stripped and blotted for total EGFR (bottom),
and after additional stripping, blotted for FAK (mAb 77; middle). preimmune IgG, allowed to adhere to FN, and then lysed and
B: T-HEp3 (T) cells were plated on FN or on PLL (see Experimental Procedures). immunoprecipitated with anti-EGFR antibody. The immunopre-EGFR was immunoprecipitated as in Figure 1D, and blotted for phosphotyro-
cipitates were tested by Western blotting for EGFR and phos-sine (RC-20, top and third panel) and total EGFR (second panel). The mem-
brane was reblotted for FAK (bottom panel). pho-EGFR content. As shown (Figure 7C), disruption of uPAR/
C: T-HEp3 cells transfected with vector (Tvec) or vector expressing FRNK (TFRNK) 51 association by anti-uPAR antibody strongly reduced the
were plated on FN. EGFR was immunoprecipitated from 1 mg of cell lysate extent of EGFR-phosphorylation. Similar reduction in EGFR
protein as in Figure 1D and analyzed for 5 (top) and total EGFR (bottom).
phosphorylation was obtained with HT1080 cells treated withIsotype-matched IgG was used as negative control.
D: Tvec or TFRNK were plated on FN or PLL (see Experimental Procedures). EGFR R2 antibody (results not shown).
and P-EGFR were determined as in B. Overall, our results indicate the existence of a functional link
between the uPA-induced integrin activation by uPAR and the
FN-induced activation of EGFR. We tested the effect of uPAR/
51/EGFR complex disruption on tumor growth in vivo by
the role of EGFR as a downstream effector of the uPA/uPAR
affecting two individual targets. Assuming that the ERK activat-induced signal to ERK, uPAR-rich T-HEp3 cells were “acid-
ing signal required for in vivo growth is uPAR-initiated andstripped” to remove endogenous uPA and treated with 10 nM
EGFR-mediated, theoretically, the disruption of any one of thepro-uPA for 10 min. We first examined whether this treatment
components should inhibit tumor growth. We used uPAR/integ-affected the integrin/EGFR association. The result in Figure 7A
rin disrupting treatment with anti-uPAR antibody (Figure 7C andshows that binding of uPA to uPAR strongly increased the 5/
Aguirre Ghiso et al., 1999) and the EGFR-kinase inhibitorEGFR association. In a similar experimental setup, the effect of
AG1478, individually or together, to pretreat the T-HEp3 cellsuPA on EGFR and ERK activation was examined. This treatment
prior to their inoculation on the CAM. Cells preincubated withinduced both EGFR and ERK activation (Figure 7B). Moreover,
IgG served as positive control for tumor growth. Each of the 5while the EGFR inhibitor AG1478 did not affect the basal levels
CAMs per group received 5 105 cells, and 3 days postinocula-of active ERK, it completely blocked uPA-stimulated ERK phos-
tion, the inoculated areas of CAMs were excised and dissociatedphorylation (Figure 7B). Similar results were obtained using the
with collagenase, and the tumor cells were counted. The resultstruncated dominant negative mutant of EGFR (EGFRCD533)
in Figure 8 show that treatment with anti-uPAR antibody was(results not shown), suggesting that EGFR kinase activity and
more efficient in reducing tumor cell growth than the AG1478dimerization are required for ERK activation by uPA/uPAR. To
treatment, possibly because it affects the very early interactionindependently test this idea, we tested whether an anti-uPAR
between the inoculated cell and the FN-containing ECM of CAM.antibody that we previously showed to disrupt uPAR/integrin
Treatment with the inhibitor was less effective, possibly becauseinteraction and reduce the signal to ERK in T-HEp3 cells (Aguirre
its influence is more transient. The combined treatment was theGhiso et al., 1999) would reduce EGFR phosphorylation. T-HEp3
cells were preincubated either with anti-uPAR antibody or with most efficient, allowing only 0.5 population doublings in 3 days.
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Does high uPAR expression have a functional
role in EGFR activation?
Specific ligands working through paracrine or autocrine loops
are well-established activators of EGFR (Schlessinger, 2000),
but we found no indication that ligand expression could explain
the difference in EGFR activation (Figure 2). It was previously
shown that following integrin/matrix interaction, the EGFR can
become phosphorylated and can activate ERK (Moro et al.,
1998). The authors concluded that the activation, which repre-
sented only a fraction of that achieved by EGF treatment, oc-
curred only in cells with abundant EGFR expression and even
then, if EGF or serum was absent, the activation of ERK and
entry into S phase did not result in cell division. In contrast, in
the D-HEp3 and AS24 cells, which had high EGFR expression,
the EGFR was not activated, while in the T-HEp3 and LK25
cells, with low EGFR but high uPAR, it was strongly activated
in the basal state and induced by adhesion to FN (Figure 1), butFigure 8. The effect of anti-uPAR antibody, EGFR kinase inhibitor AG1478,
and the combination of the two on T-HEp3 cells growth on CAM not substantially further increased by addition of EGF (results
T-HEp3 cells pretreated for 24 hr with 1 M AG1478 (AG) or untreated were not shown). Similarly, using specific antibodies, we found no
incubated with anti-uPAR (R2, 10 g/ml) or isotype-matched IgG 30 min evidence that either a constitutively active truncated receptor,
prior to inoculation on the CAM. The CAMs were collected after 72 hr and EGFRvIII, or EGFR heterodimerization with other members of
tumor cells counted (see Experimental Procedures). Number of population
the erbB family (erbB2, 3, or 4), were responsible for its activationdoublings is plotted. The median population doubling for each treatment
(results not shown).is indicated. P  0.01 IgG versus AG, R2, and R2AG; P  0.05 AG versus
R2, R2AG; P 	 0.0582 R2 versus R2AG (although there is observable While clues implicating known mechanisms of EGFR activa-
difference between the last two treatments, values did not reach statistical tion were not found, the experimental results pointed to uPAR as
significance), as determined by Mann-Whitney test.
having a functional role. First, the fraction of integrin-associated
EGFR, and that of EGFR-associated integrin, was found to be
10-fold greater in cells overexpressing uPAR. This was true
both for the parental T-HEp3 cells, where the overexpressed
We suspect that the lack of complete growth inhibition by the uPAR constitutively associates with the 51 integrin, and for
individual treatments and the increased effect of the combined D-HEp3 cells overexpressing uPAR by transfection (Figure 5B).
treatment reflect the transient nature of the interventions and In addition, in HT1080 fibrosarcoma cells transfected with
not the presence of separate signaling pathways from uPAR uPAR-antisense under tetracycline inducible promoter, down-
and from EGFR to ERK. regulation of uPAR expression by removal of tetracycline (tet-
off) reduced the integrin/EGFR association (results not shown).
Likewise, active EGFR colocalized with the 1 integrin (FigureDiscussion
3D), and 1-integrin colocalized with uPAR when the latter was
overexpressed (Aguirre Ghiso et al., 2001). Finally, the uPARThe findings presented in this manuscript lead to the unex-
structure/function analysis showed that FN-dependent EGFRpected conclusion that uPAR, a GPI-linked protease receptor,
phosphorylation was strongest in D-HEp3 cells transfected withcan influence the state of phosphorylation and signaling activity
full length uPAR, and even more so in cell transfected with theof the membrane receptor tyrosine kinase, EGFR, and that this
uPARnc in which domain D1 cannot be cleaved by proteaseseffect is independent of EGFR ligands and does not require
(Figure 5F). EGFR phosphorylation in D-HEp3 cells transfectedhigh EGFR expression. Our previously published and current
with the truncated D2D3 mutant was marginal. These resultsdata, obtained mainly using HEp3 human carcinoma cells, lead
show that uPAR can activate EGFR, and that D1 per se, or theus to the following model: in cells with low uPAR, which are
effect its presence has on uPAR conformation, is necessary fordormant in vivo (Aguirre Ghiso et al., 1999; Yu et al., 1997), the
the initiation of the signal that leads to EGFR activation. This is
51 integrin exists in an inactive state and associates poorly
supported by published results showing that D1 may be required
with EGFR, and in spite of its high expression, both under basal for uPAR interaction with integrins (Montuori et al., 1999, May
conditions or after cell adhesion to FN, EGFR is not phosphory- et al., 2000).
lated. In cells with high uPAR (T-HEp3, LK25, and D-HEp3 engi-
neered to reexpress uPAR), this receptor, in presence of uPA, Regulation by uPAR of integrin activity
interacts frequently with and activates 51, leading, in the Until the structures and sites of interaction of uPAR, integrin,
presence of FN, to the formation of a multiprotein complex that and EGFR, and very likely other proteins, are solved, the precise
contains at the very least FAK and EGFR, and that subsequently mechanism of signal propagation from uPAR to ERK cannot be
causes robust ERK activation. In contrast, in cells expressing conclusively established. It appears, however, that uPAR may
very low levels of uPAR, the very small fraction of EGFR that activate the 51 integrin by a mechanism similar to that in-
associates with the integrin is not phosphorylated. Inhibition of voked for integrin activation by Mn2 or activating antibodies
EGFR-kinase appears to extinguish the entire uPAR-induced such as TS2/16 (Bazzoni et al., 1995, 1998). Brief incubation of
signal to ERK indicating the important role of EGFR in mediating low uPAR, D-HEp3 cells with 1.5 mM Mn2 or with TS2/16
antibodies induced a degree of FN-dependent EGFR phosphor-this signal.
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ylation similar to transfection with uPAR (Figure 5). Functional maximal FN-induced EGFR and ERK activation. This conclusion
is based on the observations that phosphorylated FAK, andmodulation of 2 and 3 integrins by uPAR has been described
(Todd and Petty, 1997; Ossowski and Aguirre Ghiso, 2000). other phosphoproteins, were associated with EGFR only in cells
with high uPAR growing in vivo or following adhesion to FNOthers have shown that EGFR activation by FN was dependent
on high EGFR levels (Moro et al., 1998) or the mere presence (Figure 6A and 6B), and that expression of FRNK in T-HEp3
cells drastically reduced the integrin/EGFR association andof 51 integrins (Kuwada and Li, 2000). It appears that in some
cells 51 is active, or becomes activated, when exposed to FN-induced EGFR activation. We previously showed that over-
expression of uPAR increased the phosphorylation of FAK onthe ligand. In contrast, we found that in the absence of uPAR
in D-HEp3, AS24, and HT1080 cells upon uPAR downregulation, Tyr-397, increased phospho-Src association with FAK, and
caused Ras and ERK activation (Aguirre Ghiso, 2002), and thatthe integrins are inactive, such that under conditions that allow
signaling of T-HEp3 cells, plating these cells on FN does not FRNK inhibited Ras and ERK activation in T-HEp3 cells. This,
combined with the FRNK-mediated EGFR inhibition shown here,activate integrin signaling. However, increasing uPAR expres-
sion activates 51 integrins as evidenced by their ability to suggests that similar to the integrin and growth factor-induced
EGFR activation, FAK may also be bridging the uPAR-induced,organize surface FN-fibrils, increase adherence to FN (Aguirre
Ghiso et al., 1999, 2001), activate EGFR, and initiate a signal ligand independent EGFR activation of the classical EGFR-Ras-
ERK mitogenic pathway. The fact that FRNK displaces FAKtransduction pathway to ERK. Moreover, we have previously
shown that addition of soluble uPAR to D-HEp3 and AS24 cells from focal contacts in T-HEp3 cells and reduces FAK, Ras, and
ERK activation suggests that as reported by Sieg et al. (2000),caused rapid ERK activation, suggesting that it is the physical
interaction between these two proteins that changes integrin structural integrity of EGFR-FAK and, in our case, uPAR/51
must be present to propagate the mitogenic signal from FN andfunction (Aguirre Ghiso et al., 1999). Previous studies have
shown that ligand binding or aggregation of integrins facilitates uPA.
their interaction with growth factor receptors producing syner-
gistic or additive signaling at the MAPK level (Miyamoto et al., The consequence of EGFR-activation by uPAR
to tumor growth1996; Kuwada and Li, 2000). The possibility exists that uPAR
may affect the membrane distribution of integrins and EGFR We do not know the precise mechanism of EGFR activation in
the multimeric complex we describe here. However, the factand that in some cells, in which integrin function may be affected
by transdominant inhibitors such as other integrins or tetraspan- that integrin aggregation can induce EGFR phosphorylation (Mi-
yamoto et al., 1996) suggests that uPAR may serve this functionins (Diaz-Gonzalez et al., 1996; Hemler, 1998; Hodivala-Dilke
et al., 1998), exposure to a ligand may be insufficient to relieve in HEp3 cells, and that this may result in the assembly of a
large multimolecular complex of phosphorylated proteins. Thethis inhibition.
presence of high uPAR maintains high ERK activity through a
pathway that appears to have similarity to the “classical” ligand-EGFR is the mediator of the uPAR-induced
signal to ERK growth receptor induced pathway (Schlessinger, 2000), but re-
quires no ligand for in vivo tumor cell proliferation. The conclu-Our results linking uPAR overexpression with EGFR and ERK
activation prompted the question of the role of EGFR as the sion that EGFR ligand plays no role in in vivo proliferation of
these cells is further reinforced by the observation that D-HEp3mediator of the uPAR-induced signal to ERK. The intracellular
domain of EGFR has kinase activity that is required for auto- cells, which are fully responsive to EGF (Figure 2C), had no
active EGFR, and no association with phosphorylated proteins,phosphorylation and phosphorylation of EGFR substrates (Ull-
rich et al., 1984) and is inhibited by specific inhibitors such when maintained in vivo (Figure 6A). Although we have not yet
performed an extensive screen of cell lines or primary tumorsas AG1478, a tyrphostin (Daub et al., 1996). As expected, the
FN-induced EGFR phosphorylation was almost completely for the presence of this signaling complex, we have some indica-
tions that it is not limited to HEp3 and HT1080 cells. If foundblocked in T-HEp3 cells treated with AG1478 or in T-HEp3
cells expressing the truncated, dominant negative EGFR. More to be true for other cancers, this conclusion may have profound
importance for cancer therapy, since the uPAR-FN-inducedimportantly, ERK activation was reduced to basal levels by both
EGFR inhibitory approaches. Two additional experimental re- pathway of EGFR activation would not be sensitive to blocking
of the EGFR-ligand interaction. In support of this conclusion,sults linked uPAR function to EGFR activation of ERK. First, in
cells depleted of endogenous uPA, treatment with exogenous CaCo colon carcinoma cells transfected with 5-integrin and
plated on FN were not growth inhibited by function-blockingpro-uPA increased the integrin/EGFR association. Second,
treatment with anti-uPAR antibody, which causes “deactivation” anti-EGFR monoclonal antibody 225 (Kuwada and Li, 2000).
These cells do not express detectable levels of uPAR (resultsof integrin and loss of active ERK (Aguirre Ghiso et al., 2001),
not shown), suggesting that other pathways of integrin-inducedalmost completely blocked FN-induced EGFR phosphorylation.
EGFR activation may also be resistant to inhibition by EGFRThese results place the EGFR downstream of uPAR-induced
antagonists. Our results unveil a model whereby highly malig-integrin activation and identify it as a mediator of uPAR-induced
nant human carcinoma cells, through overexpression of uPAR,ERK activity. Moreover, the results indicate that both kinase
are able to subvert and utilize a tightly regulated EGFR pathwayactivity and, probably, dimerization of EGFR are required for
to gain matrix-derived proliferative advantage.mediation of the uPA/uPAR signal to ERK.
Experimental proceduresIs FAK involved in uPAR induced EGFR
and ERK activation? Cell lines, transfection, and culture conditions
We showed that in addition to high uPAR expression, active Human epidermoid carcinoma HEp3 (T-HEp3) (Toolan, 1954) serially pas-
saged on the chorioallantoic membrane (CAM) of 9- to 10-day-old chickand properly localized FAK (Aguirre Ghiso, 2002) is required for
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embryos (Specific Pathogen-Free Avian Supply, North Franklin, CT) was was developed using XOMAT film (Kodak, Rochester, NY) with intensifying
screens after exposure for 4–24 hr at 80
C.used as a source of tumorigenic cells. The source of “spontaneous” dormant
tumor cells (D-HEp3) was HEp3 cells passaged in culture 100–170 times
Growth of control and treated tumor cells on CAMs(Ossowski and Reich, 1980), with 20% of uPAR found in tumorigenic cells
Subconfluent cell monolayers (see figure legends for details) treated with 1(Aguirre Ghiso et al., 1999). LK25 (high uPAR, tumorigenic) is a clone of
M AG1478 (Calbiochem, San Diego, CA) or left untreated for 24 hr in serum-HEp3 cells transfected with vector LK444; AS24 (uPAR 20% of T-HEp3,
free media were detached with 2 mM EDTA in PBS, washed, and inoculateddormant) is a clone of T-HEp3 transfected with LK444 vector expressing
on the CAMs (5  105 cells per CAM) of 9- to 10-day-old chick embryos.antisense uPAR-mRNA (Yu et al., 1997; Aguirre Ghiso et al., 1999). T-HEp3
In some experiments, prior to inoculation, the cells were incubated for 30expressing FAK-related-non-kinase (FRNK) or vector transfected control
min at 37
C with anti-human uPAR mAb (R2; 10 g/ml) (kindly provided bywere as described previously (Aguirre Ghiso, 2002). Transfections were per-
Dr. Michael Ploug, Finsen Laboratory), anti-EGFR mAb (mAb 225; 10 g/formed with FuGENE (Roche, Indianapolis, IN) under recommended condi-
ml), or isotype matched IgG (Sigma Chemical, St. Louis, MO) as control. Attions.
indicated times postinoculation, CAMs were excised, enzymatically dissoci-Expression constructs of uPAR and uPAR mutants were generated as
ated, and tumor cells in single-cell suspensions were counted (Aguirre Ghisofollows. Full-length uPAR-cDNA in pCDM8 (Kook et al., 1994) was subcloned
et al., 1999). All antibodies used in vivo or in culture were free of azide.in the Xho1 site of pBS-SK (Stratagene, La Jolla, CA) (generating pBS-
The antibodies used in vivo had 24 pg/ml endotoxin measured by theuPAR). For wild-type uPAR, full-length cDNA fragment of uPAR was spliced
PyrogenPlus test from Biowhittaker (Walkersville, MD).out of pBS-uPAR using HindIII. The noncleavable uPAR mutant (protease
To analyze EGFR phosphorylation and complex formation in vivo, 2 cleavage sites in the domain 1 and 2 linker region abolished) was prepared
105 T-HEp3 and 1  106 D-HEp3 were inoculated on the CAM. Following 7by mutating R83K, Y87C, R89K, and R91K. From pBS-uPAR, two overlap-
days of growth in vivo, tumors were collected in 1% NP-40 lysis buffer (1%ping PCR fragments amplified by 5-GAGCTGCCCAAGCTTCATGGGTC-3
NP-40, 50 mM Tris-HCl, 150 mM NaCl, 1 mM orthovanadate, 1 mM NaFl,with 5-GGAATAGGTACCAGCCTTGCCAGA-3 and 5-TGGCCGGGCT
200 KIU/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mM PMSF, 5GGTACCTGTTCC-3 with 5-GGGATTTCAAGCTTAGGTCCAGAG-3 prim-
mM EDTA [pH 8]), snap-frozen in liquid nitrogen, thawed, homogenized,ers, spliced together using a novel Kpn1 site at codon 85 generating a
kept on ice for 1 hr, cleared of debris by centrifugation, and immunoprecipi-template containing R83K and Y87C mutations, were subcloned into
tated for EGFR as described below. CAM tissue was used as controls forpCDNA3.1-Hyg (Invitrogen, Carlsbad, CA). Using the resulting template, two
the specificity of the anti-human EGFR mAb 225.overlapping PCR fragments containing R89K and R91K mutations, amplified
by 5-GAGCTGCCCAAGCTTCATGGGTC-3 with 5-GCATTCGAGGTACTT
FACS analysisGCTTTTGGAAC-3 and 5-GTTCCAAAAGCAAGTACCTCGAATGC-3 with
Cells were detached with 2 mM EDTA in PBS and resuspended in cold PBS5-GGGATTTCAAGCTTAGGTCCAGAG-3 primers, were spliced together
with Ca2, Mg2, and 1% FBS at 107 cells/ml. Anti-EGFR mAb225, or isotypeusing a Taq 1 site. For the mutant expressing only domains 2 and 3 of uPAR
matched IgG, was added to 5  105 cells at 10 g/ml, incubated at 4
C for(D2D3), sequence encoding domain one was removed, thereby joining the
30 min, and after two washes, incubated for 30 min at 4
C with FITC-signal sequence with domains 2 and 3. From pBS-uPAR, a 100 bp PCR
conjugated goat anti-mouse (1 g/ml) IgG. The cells were washed twice,fragment containing the signal sequence, amplified by 5-GAGCTGCCCAA
fixed in 5% formaldehyde in PBS, and analyzed in FACSCalibur (BectonGCTTCATGGGTC-3 with 5-ACTGCATGCACTCGAGGCCCCAA-3 prim-
Dickinson) using 488 nm excitation wavelength.ers, was ligated 5 of the cDNA of D2D3, which was spliced out of pBS-
uPAR with 5 Taq1 and 3 HindIII cuts. The resulting fragments of wild-type
Immunoprecipitation (IP) and immunoblotting (IB)uPAR, noncleavable uPAR, and D2D3 were cloned nondirectionally in the
Subconfluent monolayers were washed with PBS and lysed with 1% NP-HindIII site of pCDNA3.1-Hyg. The correct orientation was verified by restric-
40 (for IP) or RIPA (1% Triton X 100, 140 mM NaCl, 10 mM Tris, 0.025%tion mapping after Pst1 digestion and sequencing (GeneWiz, New York,
NaN3, 0.1% SDS) (for IB) buffers with protease and phosphatase (1 mMNY). D-HEp3 cells transfected with the uPAR constructs in FuGENE were
orthovanadate, 1 mM NaFl) inhibitors. Protein concentration was determinedselected with hygromycin (Clontech, Palo Alto, CA) (100 g/ml) and main-
by BioRad Protein Assay (BioRad, Hercules, CA). For direct IB, 20 to 50 g
tained in 100 g/ml hygromycin. uPAR expression was determine in pooled
of total protein was analyzed. For IP, total protein (0.5 to 1.5 mg) was
clones by immunoblot analysis (see Figure 5E and Aguirre Ghiso, 2001).
precleared with protein-G-agarose for 1 hr at 4
C and the supernatant was
All cells grown in culture were maintained in DMEM with 10% FBS with
incubated with antibodies against human EGFR (mAb 225, from hybridoma
or without appropriate concentration of drug.
obtained from ATCC, Rockville, MD; Mouse Ab5, Calbiochem, San Diego,
CA), 1 integrin (mAb TS2/16, Pierce Endogen, Rockford, IL), and 51
RT-PCR and Northern analysis integrin (mAb VLA5, Chemicon International, Temecula, CA) overnight at
Total RNA from 1  107 T-HEp3, D-HEp3, LNCaP (positive control for 4
C, and after washing the immunoprecipitates were analyzed by IB. SDS-
EGF), MCF-7 (positive control for HB-EGF), and MDA231 (positive control PAGE and IB were performed as previously described (Aguirre Ghiso et al.,
for TGF- and -cellulin) serum-starved for 24 hr was extracted using an 1999) using antibodies against ERK1/2 (mAb MK12), active-EGFR (mAb 74),
Ultraspec RNA isolation system (Biotecx Laboratories, Houston, TX). For FAK (mAb 77), phosphotyrosine (PY-20 and RC-20) (all from Transduction
RT-PCR, cDNA was made from total RNA using SuperScript First-Strand Laboratories Lexington, KY), human EGFR (rabbit polyclonal anti-EGFR,
Synthesis System (Life Technologies, Rockville, MD). PCR amplification was provided by Dr. Paolo Fedi, Mount Sinai School of Medicine; or mAb 14,
performed with the following primers: 5-ACCAGAAGTCCTGAAACTAAT-3 NeoMarkers, Union City, CA), phospho-ERK1/2 (mAb E4, Santa Cruz Bio-
and 5-TCTCTCACACCTTGCTCCAAT-3 for -cellulin; 5-TCTCAACACAT technology Santa Cruz, CA), uPAR (R2), 1 integrin (anti-CD29, NeoMarkers),
GCTAGTGGCTGAAATCATG-3 and 5-TCAATATACATGCACACACCAT or 5 integrin (anti-5 rabbit polyclonal antibody, Chemicon). When neces-
CATGGAGGC-3 for EGF; and 5-TCATCATCTCTGCCCCCTCT-3 and 5- sary, the membranes were stripped with stripping buffer (62.5 mM Tris [pH
TCCGACGCCTGCTTCACCAC-3 for GAPDH. 300 bp PCR-amplified frag- 6.8], 2% SDS, 100 mM -mercaptoethanol) for 30 min at 50
C, and washed
ment of human amphiregulin, for PCR positive control, and associated prim- with TBST. When indicated, the bands were quantitated by laser densitome-
ers were provided by Dr. Jonathan Licht (Mount Sinai School of Medicine). try using GelScan XL (Pharmacia, Upsala, Sweden), the optical density units
PCR primers for TGF-were provided by Dr. Paolo Fedi (Mount Sinai School were normalized to controls and, graphs generated with CA-Cricket Graph III.
of Medicine).
For Northern blot analysis, 32P-labeled TGF-, HB-EGF, and GAPDH Immunofluorescence microscopy
probes were generated by random priming (DECA prime II DNA labeling kit, Cells grown on coverslips were fixed and processed as previously described
Ambion, Austin, TX) of plasmid DNA for TGF- (from ATCC TGF-1-10-925 (Aguirre Ghiso et al., 2001).Cells were stained with anti-1-integrin (AIIB2,
PLASMID 59950) and PCR generated fragments for HB-EGF and GAPDH. 4 g/ml, Developmental Study Hybridoma Bank, University of Iowa, Ames,
50 g of total RNA was transferred to Hybond nylon membranes (Amersham IA) and anti-activated-EGFR (mAb 74, 2 g/ml) antibodies in 0.1% BSA/
Life Sciences, Buckinghamshire, UK), and processed as previously de- PBS, or with vehicle alone. After washing and blocking, secondary antibody
(FITC-conjugated anti-rat IgG at 1:400, Sigma; AlexaRed-conjugated anti-scribed (Yu et al.) for signal development using 32P-labeled probes. The signal
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Aguirre Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., and Ossowski, L. (2001).mouse IgG at 1:1000, Molecular Probes, Eugene, OR) in 0.1% BSA/PBS
Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK)containing DAPI was added. Standard epifluorescence was captured with an
activity ratios that determine carcinoma cell proliferation or dormancy inAxioskop epifluorescence photomicroscope (Zeiss, Oberkochen, Germany)
vivo. Mol. Biol. Cell 12, 863–879.and confocal microscopy was performed using a TCS SP spectral confocal
laser scanning microscope (Leica Microsystems, Heidelberg, Germany). Andreasen, P.A., Kjøller, L., Christensen, L., and Duffy, M.J. (1997). The
urokinase-type plasminogen activator system in cancer metastasis: a review.
Fibronectin and uPA stimulation Int. J. Cancer 72, 1–22.
Subconfluent cell monolayers (see below for specific conditions and treat-
Bazzoni, G., Shih, D.T., Buck, C.A., and Hemler, M.E. (1995). Monoclonalments) were serum-starved for 24 hr, detached with 2 mM EDTA, and plated
antibody 9EG7 defines a novel beta 1 integrin epitope induced by solubleon plastic dishes precoated for 24 hr in 4
C with 10 g/ml human fibronectin
ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270, 25570–(FN) or poly-lysine (PLL) (Sigma) as controls. In some experiments, T-HEp3
25577.were pretreated for 20 min with 10 g/ml CRM197 and plated in the presence
of 10 g/ml CRM197, for 15 min with 1 M AG1478 and plated in the Bazzoni, G., Ma, L., Blue, M.L., and Hemler, M.E. (1998). Divalent cations
presence of 1 M AG1478, or were transiently transfected for 48 hr with and ligands induce conformational changes that are highly divergent among
vector expressing CD533-EGFR, dominant-negative EGFR (provided by Dr. beta1 integrins. J. Biol. Chem. 273, 6670–6678.
Axel Ullrich, Max Planck Institute), and plated on FN or PLL. To test the
Bissell, M.J., Weaver, V.M., Lelievre, S.A., Wang, F., Petersen, O.W., andactivation of 51, D-HEp3 cells were plated in medium with 1.5 mM MnCl2
Schmeichel, K.L. (1999). Tissue structure, nuclear organization, and geneor were preincubated for 30 min at 37
C with 10 g/ml TS2/16 or isotype-
expression in normal and malignant breast. Cancer Res. 59, 1757–1763.matched IgG and used to determine EGFR activation. Disruption of the
uPAR/integrin complex in T-HEp3 cells was achieved by incubation of the Cary, L.A., and Guan, J.L. (1999). Focal adhesion kinase in integrin-mediated
cells with 10 g/ml anti-uPAR R2 or isotype-matched IgG for 30 min at 37
C signaling. Front. Biosci. 4, D102–D113.
prior to plating. D-HEp3 cells transfected with wild-type and mutant uPAR,
Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. (1996). Role of transacti-or T-HEp3 transfected with vector or vector expressing FRNK were plated
vation of the EGF receptor in signalling by G-protein- coupled receptors.on FN or PLL. After 20 min, adherent cells were washed with PBS, lysed
Nature 379, 557–560.with 1% NP-40 or RIPA buffers with protease and phosphatase inhibitors,
and analyzed by IP or direct IB. For uPA treatment, subconfluent monolayers Diaz-Gonzalez, F., Forsyth, J., Steiner, B., and Ginsberg, M.H. (1996). Trans-
of T-HEp3 cells were serum-starved for 24 hr, preincubated for 15 min with dominant inhibition of integrin function. Mol. Biol. Cell 7, 1939–1951.
or without 1 M AG1478, acid-stripped of uPAR bound uPA for 3 min (using
Giancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science 285,cold 0.05 M glycine-HCl in 0.1 M NaCl [pH 3]), and neutralized using 0.5 M
1028–1032.Tris-HCl (pH 7.8) and incubated for 10 min with 10 nM single chain uPA
(scuPA) (provided by Dr. Jack Henkin, Abbott Laboratories) in the presence Goishi, K., Higashiyama, S., Klagsbrun, M., Nakano, N., Umata, T., Ishikawa,
of 200 KIU/ml aprotinin (to inhibit protease-dependent effects of uPA) with M., Mekada, E., and Taniguchi, N. (1995). Phorbol ester induces the rapid
or without AG1478. Cells were lysed with 1% NP-40 with protease and processing of cell surface heparin-binding EGF-like growth factor: conver-
phosphatase inhibitors and analyzed by IP or direct IB. sion from juxtacrine to paracrine growth factor activity. Mol. Biol. Cell 6,
967–980.
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